{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:53:17Z","timestamp":1791445997686,"version":"4.3.3"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","funder":[{"name":"Department of Science and Technology India","award":["No. CRG\/2019\/003878; dated 5th February, 2020)"],"award-info":[{"award-number":["No. CRG\/2019\/003878; dated 5th February, 2020)"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      This study evaluated if [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]HYNIC-prostate-specific membrane antigen (PSMA)-11 scintigraphy presents a clinically viable imaging alternative to [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PSMA-11 PET\/computed tomography (CT) for disease evaluation in prostate cancer (PC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this prospective study, 106 patients diagnosed with prostate cancer were recruited. A total of 51 patients were assigned in the initial staging cohort and the remaining 55 patients in the re-staging cohort (comprising biochemical recurrence, metastatic castration-resistant prostate cancer, and metastatic hormone-sensitive prostate cancer). Imaging with [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc] HYNIC-PSMA-11 was conducted within one week following [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PSMA-11 PET\/CT. Whole-body planar [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]HYNIC-PSMA-11 images were obtained at 2-, 4-h, and regional SPECT\/CT at 3-h. A comparative detection efficiency of [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]HYNIC-PSMA-11 versus [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PSMA-11 PET\/CT was evaluated by consensus for the involved lesions\/sites. A correlation analysis was carried out between maximum standardized uptake values of PSMA PET and percent quantitative lesion uptake values of PSMA SPECT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]PSMA-11 PET\/CT detected 896 metastatic lesions, where HYNIC-PSMA-11 detected 761 lesions, offering an overall sensitivity of 85%. The sensitivity of [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc] HYNIC-PSMA-11 SPECT\/CT was 100% for primary\/visceral lesions, 92% for skeletal lesions, 75.3% for distant lymph nodes and 67.4% for locoregional lymph nodes. A substantial agreement (\n                      <jats:italic toggle=\"yes\">\u03ba =<\/jats:italic>\n                      0.78,\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.0001) was seen between two imaging modalities. UCSF Cancer of the Prostate Risk Assessment score based disease staging matched with the disease staging demonstrated by both the imaging techniques. A significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) correlation was seen between the quantitative parameters of the two techniques both for primary (\n                      <jats:italic toggle=\"yes\">r =<\/jats:italic>\n                      0.96) and metastatic (\n                      <jats:italic toggle=\"yes\">r =<\/jats:italic>\n                      0.79 for skeletal and\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = 0.65 for lymph nodes) lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]HYNIC-PSMA-11 SPECT\/CT offers a potentially viable and cost-effective substitute for PSMA-PET for disease staging, quantification and response assessment to PSMA-targeted radiotherapies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002191","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:01:04Z","timestamp":1782147664000},"page":"1265-1273","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A comparative assessment of [99mTc] HYNIC-PSMA-11 scintigraphy in prostate cancer as a potential substitute for disease evaluation with [68Ga] PSMA-11 PET\/CT imaging"],"prefix":"10.1097","volume":"47","author":[{"given":"Monika","family":"Hooda","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya P.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravimohan","family":"Mavuduru","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrawan K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"R1-20261008","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20261008","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3390\/curroncol30020178","article-title":"Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis.","volume":"30","author":"Berenguer","year":"2023","journal-title":"Curr Oncol"},{"key":"R3-20261008","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent.","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R4-20261008","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.ju.0000131621.61732.6b","article-title":"Contemporary impact of transrectal ultrasound lesions for prostate cancer detection.","volume":"172","author":"Onur","year":"2004","journal-title":"J Urol"},{"key":"R5-20261008","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.09.035","article-title":"Evaluating biparametric versus multiparametric magnetic resonance imaging for diagnosing clinically significant prostate cancer: an international, paired, noninferiority, confirmatory observer study.","volume":"87","author":"Twilt","year":"2025","journal-title":"Eur Urol"},{"key":"R6-20261008","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"R7-20261008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","article-title":"Meta-analysis of 18 F-PSMA-1007 PET\/CT, 18 F-FDG PET\/CT, and 68Ga-PSMA PET\/CT in diagnostic efficacy of prostate Cancer.","volume":"23","author":"Yu","year":"2023","journal-title":"Cancer Imaging"},{"key":"R8-20261008","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION Trial).","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"R9-20261008","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry.","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J Nucl Med"},{"key":"R10-20261008","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/RLU.0000000000003702","article-title":"Comparing 99mTc-PSMA to 99mTc-MDP in prostate cancer staging of the skeletal system.","volume":"46","author":"Kabunda","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R11-20261008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/a-1035-9052","article-title":"Determination of whole-body tumour burden on [68Ga]PSMA-11 PET\/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.","volume":"58","author":"Michalski","year":"2019","journal-title":"Nuklearmedizin"},{"key":"R12-20261008","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MNM.0000000000001361","article-title":"Comparison of the diagnostic utility of 99mTcPSMA scintigraphy versus 68Ga-PSMA-11 PET\/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.","volume":"42","author":"Singh","year":"2021","journal-title":"Nucl Med Commun"},{"key":"R13-20261008","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/RLU.0000000000005754","article-title":"Can 99mTc-PSMA SPECT\/CT presenting mirror image of 68Ga-PSMA PET\/CT be used for response assessment to 177Lu-PSMA in metastatic castration-resistant prostate cancer?","volume":"50","author":"Hooda","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R14-20261008","doi-asserted-by":"crossref","first-page":"1118531","DOI":"10.3389\/fmed.2023.1118531","article-title":"Quantitative liver SPECT\/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis.","volume":"10","author":"Kaur","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R15-20261008","doi-asserted-by":"crossref","first-page":"20220886","DOI":"10.1259\/bjr.20220886","article-title":"Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas.","volume":"96","author":"Kleiburg","year":"2023","journal-title":"Br J Radiol"},{"key":"R16-20261008","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.3390\/molecules27092617","article-title":"A review on the current state and future perspectives of [99mTc]Tc-Housed PSMA-i in prostate cancer.","volume":"27","author":"Brunello","year":"2022","journal-title":"Molecules"},{"key":"R17-20261008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40644-024-00693-9","article-title":"Optimizing PSMA scintigraphy for resource limited settings \u2013 a retrospective comparative study.","volume":"24","author":"Kolade","year":"2024","journal-title":"Cancer Imaging"},{"key":"R18-20261008","first-page":"332","article-title":"Head to head comparison performance of 99mTc-EDDA\/HYNIC-iPSMA SPECT\/CT and 68Ga-PSMA-11 PET\/CT: a prospective study in biochemical recurrence prostate cancer patients.","volume":"8","author":"Garc\u00eda-P\u00e9rez","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R19-20261008","doi-asserted-by":"crossref","first-page":"1271176","DOI":"10.3389\/fchem.2023.1271176","article-title":"Radiochemical and biological assessments of a PSMA-I&S cold kit for fast and inexpensive 99mTc-labeling for SPECT imaging and radioguided surgery in prostate cancer.","volume":"11","author":"Fuscaldi","year":"2023","journal-title":"Front Chem"},{"key":"R20-20261008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s41824-024-00226-4","article-title":"Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry.","volume":"8","author":"Tually","year":"2024","journal-title":"EJNMMI Rep"},{"key":"R21-20261008","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.3390\/molecules27217216","article-title":"[99mTc]Tc-PSMA-T4\u2014novel SPECT tracer for metastatic PCa: from bench to clinic.","volume":"27","author":"Maurin","year":"2022","journal-title":"Molecules"},{"key":"R22-20261008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nucmedbio.2017.01.010","article-title":"99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.","volume":"48","author":"Xu","year":"2017","journal-title":"Nucl Med Biol"},{"key":"R23-20261008","doi-asserted-by":"crossref","first-page":"1165694","DOI":"10.3389\/fonc.2023.1165694","article-title":"The efficacy of 99mTc-HYNIC-PSMA SPECT\/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer.","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"R24-20261008","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","article-title":"99mTc-PSMA SPECT\/CT versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer.","volume":"46","author":"Fallahi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R25-20261008","first-page":"1","article-title":"Direct comparison of 99mTc-PSMA SPECT\/CT and 68Ga-PSMA PET\/CT in patients with prostate cancer.","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"R26-20261008","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pros.23379","article-title":"Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET\/CT.","volume":"77","author":"Lawal","year":"2017","journal-title":"Prostate"},{"key":"R27-20261008","doi-asserted-by":"crossref","first-page":"1072437","DOI":"10.3389\/fonc.2022.1072437","article-title":"Diagnostic performance of 99mTc-HYNIC-PSMA SPECT\/CT for biochemically recurrent prostate cancer after radical prostatectomy.","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R28-20261008","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40658-022-00513-8","article-title":"Quantitative [99mTc]Tc-MDP SPECT\/CT correlated with [18F]NaF PET\/CT for bone metastases in patients with prostate cancer.","volume":"9","author":"Tanaka","year":"2022","journal-title":"EJNMMI Phys"},{"key":"R29-20261008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.122.264296","article-title":"Eligibility for 177Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in metastatic castration-resistant prostate cancer.","volume":"64","author":"Cook","year":"2023","journal-title":"J Nucl Med"},{"key":"R30-20261008","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2967\/jnumed.122.264944","article-title":"PSMA-GCK01: a generator-based 99mTc\/188Re theranostic ligand for the prostate-specific membrane antigen.","volume":"64","author":"Cardinale","year":"2023","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:00:34Z","timestamp":1791442834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002191","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"2026-03-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}